G.A. Tikhonova1, O.V. Kotov2, A.A. Markin3

1–3 Federal State Budgetary Institution of Science State Scientific Center of the Russian Federation –
Institute of Biomedical Problems of the Russian Academy of Sciences (Moscow, Russia)

An urgent task of modern medical science is the search for tools that provide diagnosis and prognosis of the human body in various pathologies, evaluation of the effectiveness of therapeutic measures, as well as monitoring of prenosological processes that have predictive value. Biomarkers have become such means – specifically and quantitatively determined objective indicators of physiological and pathological processes in the body at different levels of its integration. Despite the fact that biomarkers are widely used in clinical, experimental, aerospace, marine, environmental, sports, age-related medicine, disaster medicine, pharmacology and many other industries, it is imperative to develop and implement new, highly informative biomarkers taking into account the challenges facing humanity. The paper systematizes the available data on various classes of biomarkers and the possibilities of their application in the interests of biomedical sciences, as well as in the practice of clinical medicine. Based on the existing international classification, the whole set of categories of biomarkers in biomedical and clinical versions is shown. Their properties and areas of application are determined. Emphasis is placed on the possibilities of using biomarkers in medicine. The data presented in the review can serve as a basis for planning biomedical, clinical and pharmacological studies in terms of assessing and predicting the effects of the studied phenomena.

Tikhonova G.A., Kotov O.V., Markin A.A. Biomarkers in the practice of biology and medicine (Literature review. Part 1). Technologies of Living Systems. 2023. V. 20. № 2. Р. 18-26. DOI: https://doi.org/10.18127/j20700997-202302-02 (In Russian)

1. Biologic markers in reproductive toxicology. Washington, DC: The National Academy Press. 1989. 420 p.
2. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics. 2001. V. 69. № 3. P. 89–95.
3. Biomarkers and risk assessment: concepts and principles. IPCS. Environmental health criteria 155. Geneva: WHO. 1993. 82 p.
4. Markova O.L., Shilov V.V., Kuznetsov A.V., Metelitsa N.D. Sravnitelnaya otsenka podkhodov k probleme biomonitoringa zdorovia cheloveka otechestvennykh i zarubezhnykh issledovateley (obzor literatury). Gigiyena i sanitariya. 2020. T. 99. № 6. S. 545–550. (in Russian).
5. Ponomareva N.Yu., Mitkovskiy V.G., Yampolskaya E.N., Kochetkov A.V. Geneticheskiye issledovaniya dlya meditsiny ekstremalnykh situatsiy (obzor literatury). Meditsina ekstremalnykh situatsiy. 2017. T. 4. № 62. S. 63–74. (in Russian).
6. Zaytseva N.V., Zemlyanova M.A., Chashchin V.P., Gudkov A.B. Nauchnyye printsipy primeneniya biomarkerov v mediko-ekologicheskikh issledovaniyakh (obzor literatury). Ekologiya cheloveka. 2019. № 9. S. 4–14. (in Russian).
7. Hess S., Ozoux M.L., Gerl M. Biomarker Definition and Validation During Drug Development. Vogel H.G., Maas J., Gebauer A. (eds) Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Berlin: Springer. 2011. Р. 223—244.
8. Dancey J.E., Dobbin K.K., Groshen S., Jessup J.M. et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 2010. V. 16. № 6. P. 1745—1755.
9. Strimbu K., Tavel J.A. What are Biomarkers? Current Opinion in HIV and AIDS. 2010. V. 5. № 6. P. 463–466.
10. Atkinson A.J., Colburn W., Degrutta V. et al. Biomarkers and surrogate endpoints: preferred definition and conceptual framework. Clin. Pharmacol. Ther. 2001. V. 69. № 3. P. 89–95.
11. Don E.S., Tarasov A.V., Epshteyn O.I., Tarasov S.A. Biomarkery v meditsine: poisk. vybor. izucheniye i validatsiya. Klinicheskaya laboratornaya diagnostika. 2017. V. 62. № 1. S. 52–59. (in Russian).
12. Wang J., Balu N., Canton G. et al. Imaging biomarkers of cardiovascular disease. J. Magn. Reson. Imaging. 2010. V. 32. № 2. P. 502–515.
13. Çintesun E., Akar S., Gul A., Çintesun F.N.I. et al. Subclinical inflammation markers in hyperemesis gravidarum and ketonuria: A case-control study. J. Lab. Physicians. 2019. V. 11. № 2. P. 149–153.
14. Cowie M.R., Struthers A.D., Wood D.A., Coats A.J. et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. The Lancet. 1997. V. 350. № 9088. P. 1349–1353.
15. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R. et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. Journal of the American College of Cardiology. 2007. V. 50. № 7. P. e1–e157.
16. Wang J., Tang B., Liu X., et al. Increased monomeric CRP levels in acute myocardial infarction: a possible new and specific biomarker for diagnosis and severity assessment of disease. Atherosclerosis. 2015. V. 239. № 2. P. 343–349.
17. Sabirov I.S., Murkamilov I.T., Fomin V.V., Sabirova A.I. Prognosticheskoye znacheniye D-dimera v razvitii tromboembolicheskikh oslozhneniy pri novoy koronavirusnoy infektsii (COVID-19). The Scientific Heritage. 2021. V. 60. № 2. P. 38–46. (in Russian).
18. Minyazeva R.K., Batalova G.Yu., Sakhautdinova I.V., Gilyazova I.R. Genomnyye i proteomnyye markery i perspektivy ikh ispolzovaniya pri rake sheyki matki. Kreativnaya khirurgiya i onkologiya. 2021. T. 11. № 2. C. 166–173. (in Russian).
19. Sokova E.A., Arkhipov V.V., Mazerkina I.A., Muslimova O.V. Nekotoryye aspekty otsenki lekarstvennogo porazheniya pochek. Bezopasnost i risk farmakoterapi. 2020. T. 8. № 3. S. 123–133. (in Russian).
20. De Jong E., van Oers J.A., Beishuizen A., et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016. V. 16. P. 819–827.
21. Prikaz MZ RF № 520n ob utverzhdenii kriteriyev kachestva otsenki meditsinskoy pomoshchi ot 15 iyulya 2016 goda. (in Russian).
22. Klinicheskiye rekomendatsii MZ RF. Vnebolnichnaya pnevmoniya u vzroslykh. 2021. 126 c. (in Russian).
23. Klinicheskiye rekomendatsii MZ RF. Vospalitelnyye bolezni zhenskikh tazovykh organov. 2021. 46 c. (in Russian).
24. Coppé J.P., Desprez P.Y., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Ann. Rev. Pathol. 2010. № 5. P. 99–118.
25. Nesmiyanov P.P., Dzhayn M., Rakhmatullin T.I., Buravleva K.V., Seredenina E.M., Samokhodskaya L.M. Tsitokinovyy profil eritrotsitov perifericheskoy krovi patsiyentov s ishemicheskoy boleznyu serdtsa i khronicheskoy serdechnoy nedostatochnostyu. Tekhnologii zhivykh sistem. 2022. T. 19. № 4. S. 33–41. (in Russian).
26. Chinta S.J., Woods G., Rane A., Demaria M. et al. Cellular senescence and the aging brain. Exp. Gerontol. 2015. V. 68. P. 3–7.
27. Artemyeva O.V., Gankovskaya. L.V. Vospalitelnoye stareniye kak osnova vozrast-assotsiirovannoy patologii. Meditsinskaya immunologiya. 2020. T. 22. № 30. S. 419–432. (in Russian).
28. Ciaccio M., Agnello L. Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19). Diagnosis (Berl). 2020. V. 7. № 4. P. 365–372.
29. Yang Z., Shi J., He Z., et al. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. Aging. 2020. V. 12. P. 6037–6048.
30. Goncharova A.G., Tikhonova G.A., Goncharov I.N. Rol kardialnykh markerov v diagnostike serdechno-sosudistykh zabolevaniy posle perenesennogo SARS-CoV-2. Tekhnologii zhivykh sistem. 2022. T. 19. № 4. S. 42–51. (in Russian).
31. Santoso A., Pranata R., Wibowo A., et al. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis. Am. J. Emerg. Med. 2021. V. 44. P. 352–357.
32. Zagidullin N., Motloch L.J., Gareeva D., et al. Combining Novel Biomarkers for Risk Stratification of Two-Year Cardiovascular Mortality in Patients with ST-Elevation Myocardial Infarction. J. Clin. Med. 2020. V. 9. № 2. P. 550.
33. Chaulin A.M., Duplyakov D.V. Biomarkery ostrogo infarkta miokarda: diagnosticheskaya i prognosticheskaya tsennost. Chast 2 (obzor literatury). Klinicheskaya praktika. 2020. T. 11. № 4. C. 70–82. (in Russian).
34. Chaulin A.M., Duplyakov D.V. MicroRNAs in Atrial Fibrillation: Pathophysiological Aspects and Potential Biomarkers. International Journal of Biomedicine. 2020. V. 10. № 3. P. 198–205.
35. Jiwei Gu, Chunlian Liu, Yun Wang, Zhenghao Huo. miRNA and Cardiac Hypertrophy. Science Insights. 2019. V. 28. № 1. P. 17–24.
36. Metelskaya V.A., Gumanova N.G. Validnyye kardiospetsificheskiye biokhimicheskiye markery. Chast I. Kardiovaskulyarnaya terapiya i profilaktika. 2020. T. 19. № 4. S. 2573–2629. (in Russian).
37. Likhonosov N.P., Ayub A.Kh., Babenko A.Yu., Borovets S.Yu. Rol ingibina v regulyatsii spermatogeneza i ego klinicheskaya znachimost pri muzhskom besplodii. Urologicheskiye vedomosti. 2019. T. 9. №. 1. S. 39–45. (in Russian).
38. Shay A.N., Fedulova M.V., Kvacheva Yu.E., Shigeyev S.V. i dr. Znacheniye belkov-markerov nervnoy tkani dlya morfologicheskoy diagnostiki cherepno-mozgovoy travmy. Sudebno-meditsinskaya ekspertiza. 2017. T. 60. № 4. S. 40–45. (in Russian).
39. Roberts R.A., Aschner M., Calligaro D. et al. Translational biomarkers of neurotoxicity: Health and Environmental Sciences Institute perspective on the way forward. Toxicol. Sci. 2015. V. 148. № 2. P. 332–340.
40. O’Callaghan J.P., Sriram K. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin. Drug Saf. 2005. V. 4. № 3. 433–442.
41. Osipova T.V., Bukhman V.M. Biomarkery translyatsionnoy meditsiny. Rossiyskiy bioterapevticheskiy zhurnal. 2018. T. 17. № 1. S. 6–13. (in Russian).
42. Roberts R.A., Aschner M., Calligaro D. et al. Translational biomarkers of neurotoxicity: Health and Environmental Sciences Institute perspective on the way forward. Toxicol. Sci. 2015. V. 148. № 2. P. 332–340.
43. Kochetov A.G., Lyang O.V., Zhirova I.A. i dr. Laboratornyye issledovaniya v meditsine. Terapevticheskiy arkhiv. 2020. T. 92. № 4. S. 4–8. (in Russian).